Chengdu Kanghua Biological Products Co., Ltd. (SHE:300841)
China
· Delayed Price · Currency is CNY 61.75
-0.45 (-0.72%)
At close: Mar 9, 2026
SHE:300841 Revenue
Chengdu Kanghua Biological Products had revenue of 356.14M CNY in the quarter ending September 30, 2025, with 11.54% growth. This brings the company's revenue in the last twelve months to 1.21B, down -26.47% year-over-year. In the year 2024, Chengdu Kanghua Biological Products had annual revenue of 1.43B, down -9.23%.
Revenue (ttm)
1.21B
Revenue Growth
-26.47%
P/S Ratio
6.62
Revenue / Employee
1.95M
Employees
620
Market Cap
8.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.43B | -145.52M | -9.23% |
| Dec 31, 2023 | 1.58B | 130.67M | 9.03% |
| Jan 1, 2023 | 1.45B | 154.28M | 11.94% |
| Jan 1, 2022 | 1.29B | 253.81M | 24.44% |
| Dec 31, 2020 | 1.04B | 484.00M | 87.26% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Vazyme Biotech | 1.38B |
| Anhui Huaheng Biotechnology | 2.89B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Zhejiang Ausun Pharmaceutical | 751.12M |
| Youcare Pharmaceutical Group | 2.45B |
| Daan Gene | 765.48M |
| Acrobiosystems | 794.52M |